These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25529092)

  • 21. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients.
    Goulis I; Karatapanis S; Akriviadis E; Deutsch M; Dalekos GN; Raptopoulou-Gigi M; Mimidis K; Germanidis G; Drakoulis C; Triantos C; Zintzaras E; Bakalos G; Papatheodoridis G
    Liver Int; 2015 May; 35(5):1540-8. PubMed ID: 25368957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virological and serological tools to optimize the management of patients with chronic hepatitis B.
    Martinot-Peignoux M; Marcellin P
    Liver Int; 2016 Jan; 36 Suppl 1():78-84. PubMed ID: 26725902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B surface antigen monitoring and management of chronic hepatitis B.
    Sonneveld MJ; Zoutendijk R; Janssen HL
    J Viral Hepat; 2011 Jul; 18(7):449-57. PubMed ID: 21692954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
    Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
    Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
    Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.
    Moucari R; Martinot-Peignoux M; Mackiewicz V; Boyer N; Ripault MP; Castelnau C; Leclere L; Dauvergne A; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Antivir Ther; 2009; 14(8):1183-8. PubMed ID: 20032548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Peng CY; Lai HC; Li YF; Su WP; Chuang PH; Kao JT
    Aliment Pharmacol Ther; 2012 Feb; 35(4):458-68. PubMed ID: 22225574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
    Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
    Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients.
    Song EY; Shin Y; Roh EY; Sue S; Park MH; Kim BH; Kim W; Yoon JH; Lee YJ; Park SJ; Jung EU; Lee JH; Myung SJ; Kim YJ; Lee HS
    J Med Virol; 2011 Jan; 83(1):88-94. PubMed ID: 21108343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H; Yang RF; Wei L
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.
    Yu C; Gong X; Yang Q; Lian J; Xu K; Ruan B; Li L
    Liver Int; 2015 May; 35(5):1549-56. PubMed ID: 25312687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.
    Moucari R; Boyer N; Ripault MP; Castelnau C; Mackiewicz V; Dauvergne A; Valla D; Vidaud M; Chanoine MH; Marcellin P
    J Viral Hepat; 2011 Aug; 18(8):580-6. PubMed ID: 20487260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.
    Sonneveld MJ; Arends P; Boonstra A; Hansen BE; Janssen HL
    J Hepatol; 2013 May; 58(5):898-903. PubMed ID: 23376362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.
    Hadziyannis E; Hadziyannis SJ
    Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):185-95. PubMed ID: 24417264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients.
    Martinot-Peignoux M; Asselah T; Marcellin P
    Clin Liver Dis; 2013 Aug; 17(3):399-412. PubMed ID: 23905812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.